At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Erlotinib (Tarceva) +2 moredrug
Likely dose
Erlotinib (Tarceva) 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
In Brief
A Phase 2 clinical trial evaluating Erlotinib (Tarceva), Intra-arterial Cisplatin (PLAT), and 1 other intervention for Head and Neck Cancer. Completed, enrolled 21 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
CollaboratorsGenentech, Inc., OSI Pharmaceuticals
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedMar 2006
Primary CompletionMay 2015
Study CompletionDec 2015
TodayJul 2026
First PostedMar 17, 2006
Enrollment StartMar 1, 2006
Primary CompletionMay 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 20.3 years ago
Interventions
Erlotinib (Tarceva)drug
150 mg daily X 7 weeks
Intra-arterial Cisplatin (PLAT)drug
1 dose (150 mg/sq) per week X 4 weeks
Radiation Therapy (RAD)radiation
5 days per week X 7 weeks